International Journal of Medical and Health Sciences
DOI: 10.64823/ijmhs.2601004
Few conditions in neonatal medicine present clinicians with challenges as complex and time-sensitive as hypoxic-ischaemic encephalopathy (HIE). Despite considerable advances in obstetric care, neonatal resuscitation, and intensive care medicine, perinatal asphyxia continues to affect approximately one to three infants per 1,000 live births in high-income countries, with substantially higher rates reported in low- and middle-income settings. Survivors frequently face lifelong neurodevelopmental consequences including cerebral palsy, epilepsy, cognitive impairment, behavioural disorders, and sensory deficits.
The introduction of therapeutic hypothermia transformed neonatal neurocritical care and remains the only intervention with proven neuroprotective efficacy for moderate and severe HIE. Nevertheless, nearly half of treated infants either die or develop significant neurological impairment despite receiving optimal cooling therapy. Such observations suggest that brain injury following perinatal asphyxia cannot be fully explained by cerebral mechanisms alone.
For decades, clinical attention in HIE has focused primarily on neuronal energy failure, excitotoxicity, oxidative stress, and neuroinflammation. Although these pathways undoubtedly play central roles, severe intrapartum hypoxia rarely affects the brain in isolation. The fetus responds to oxygen deprivation through redistribution of cardiac output toward vital organs, a compensatory mechanism commonly referred to as the "brain-sparing effect." When hypoxia becomes prolonged or severe, however, these adaptive responses become overwhelmed, resulting in widespread systemic injury involving the myocardium, kidneys, lungs, liver, and gastrointestinal tract.
Among these organs, the heart and kidneys appear to exert particularly important influences on neurological recovery. Myocardial dysfunction may compromise cerebral perfusion during the vulnerable reperfusion period, while acute kidney injury alters fluid homeostasis, drug clearance, inflammatory signaling, and metabolic stability. Conversely, evolving cerebral injury can influence autonomic regulation and cardiovascular function, creating a dynamic cycle of reciprocal organ interactions.
The concept of a cardio-renal syndrome is well established in adult medicine, particularly in patients with heart failure and critical illness. In neonatology, however, a broader and more integrated understanding of the relationship between cardiac function, renal physiology, and cerebral perfusion has only recently begun to emerge. Increasing use of targeted neonatal echocardiography, near-infrared spectroscopy, continuous electroencephalographic monitoring, and novel biomarkers has highlighted the existence of a complex cardio-renal-brain axis that may significantly influence outcomes following hypoxic-ischaemic injury.
Recognition of this interconnected physiology has important clinical implications. Management strategies based solely on blood pressure thresholds or neurological examination may fail to identify occult circulatory compromise, impaired cerebral autoregulation, or evolving renal dysfunction. Precision neurocritical care therefore requires a shift from organ-specific treatment toward integrated haemodynamic assessment and individualized therapeutic decision-making.
This review explores current evidence regarding cardiovascular dysfunction, acute kidney injury, and cerebral autoregulatory disturbances in neonatal HIE, examines the physiological interactions between these systems during therapeutic hypothermia, and discusses emerging approaches that may support the development of precision haemodynamic management in neonatal neurocritical care.
For many years, neonatal hypoxic-ischaemic encephalopathy was regarded primarily as a disease of cerebral injury. Research efforts understandably focused on neuronal apoptosis, excitotoxicity, oxidative stress, mitochondrial dysfunction, and inflammatory cascades occurring within the central nervous system. This brain-centred approach led to major advances in understanding the mechanisms of primary and secondary energy failure and ultimately paved the way for the introduction of therapeutic hypothermia.
However, clinical observations have increasingly challenged the concept of HIE as an isolated neurological disorder. Infants with severe perinatal asphyxia frequently demonstrate evidence of myocardial dysfunction, pulmonary hypertension, acute kidney injury, hepatic impairment, coagulopathy, adrenal insufficiency, and gastrointestinal injury within the first hours after birth. Indeed, the severity of extracerebral organ dysfunction often parallels the degree of neurological injury and may independently influence survival and neurodevelopmental outcome.
Recent studies suggest that approximately 60–80% of infants with moderate or severe HIE exhibit some degree of cardiovascular compromise, while acute kidney injury develops in up to 50% of cooled infants. These findings indicate that systemic hypoxia-ischaemia produces a complex pattern of organ crosstalk rather than isolated cerebral injury.
During acute hypoxia, the fetus activates several adaptive mechanisms aimed at preserving oxygen delivery to vital organs. Redistribution of cardiac output occurs through peripheral vasoconstriction and preferential perfusion of the brain, heart, and adrenal glands, a physiological response commonly referred to as the brain-sparing effect.
This adaptive circulation is mediated through:
Under mild or transient hypoxic conditions, these compensatory mechanisms may successfully preserve cerebral oxygenation and limit organ injury.
However, prolonged or severe asphyxia overwhelms these protective responses.
Progressive myocardial hypoxia leads to declining cardiac output, impaired ventricular contractility, and loss of compensatory redistribution. Once systemic perfusion falls below a critical threshold, oxygen delivery to both central and peripheral organs deteriorates rapidly, initiating widespread cellular injury.
The restoration of circulation following successful resuscitation is essential for survival but paradoxically initiates additional injury pathways.
Reoxygenation triggers:
This phenomenon, commonly referred to as reperfusion injury, contributes substantially to secondary energy failure occurring during the first 6–48 hours after birth.
Importantly, these processes occur simultaneously within multiple organs.
Myocardial injury reduces systemic blood flow and oxygen delivery, renal dysfunction impairs metabolic homeostasis and inflammatory clearance, while cerebral autoregulatory disturbances increase susceptibility to fluctuations in perfusion pressure. Rather than acting independently, these injuries amplify one another through a network of haemodynamic and inflammatory interactions.
The neonatal myocardium possesses limited contractile reserve compared with older children and adults. Reduced compliance, immature calcium handling, and limited ability to augment stroke volume make the newborn heart particularly vulnerable to hypoxic injury.
Following perinatal asphyxia, myocardial dysfunction may manifest as:
Importantly, normal blood pressure does not necessarily indicate adequate systemic blood flow.
Several studies using functional echocardiography have demonstrated that infants with HIE may exhibit significantly reduced cardiac output despite maintaining blood pressure values within conventional reference ranges. Such occult low-output states may contribute to impaired cerebral perfusion during the critical period of secondary brain injury.
These observations have shifted attention away from isolated blood pressure targets toward more comprehensive haemodynamic assessment.
Historically, acute kidney injury in HIE was viewed primarily as a marker of severe asphyxia rather than an active contributor to disease progression.
Emerging evidence suggests otherwise.
Renal dysfunction may contribute to neurological injury through several mechanisms:
Experimental studies have demonstrated bidirectional communication between injured kidneys and the central nervous system mediated through inflammatory cytokines, oxidative stress pathways, and neurohumoral activation.
The kidney therefore functions not merely as an innocent bystander but as an active component of the evolving neurocritical illness.
The traditional organ-based model of neonatal intensive care may no longer adequately reflect the complexity of modern neurocritical care.
A more integrated model recognizes that:
The outcome following HIE therefore reflects not only the severity of cerebral injury but also the resilience of the entire physiological network supporting cerebral recovery.
This concept forms the basis of the neonatal cardio-renal-brain axis, an emerging framework that may help guide future strategies in individualized haemodynamic management.
The neonatal myocardium enters extrauterine life with relatively little physiological reserve. Compared with older children and adults, the newborn heart has limited capacity to increase stroke volume, making cardiac output heavily dependent on heart rate and preload conditions. Reduced ventricular compliance, immature calcium handling, fewer organized contractile elements, and limited capacity to augment stroke volume render the newborn myocardium particularly susceptible to hypoxic injury.
During perinatal asphyxia, myocardial oxygen consumption remains high despite declining oxygen delivery. Although coronary perfusion initially increases as part of the fetal adaptive response, prolonged hypoxia eventually overwhelms compensatory mechanisms, leading to myocardial ischemia and cellular injury.
In clinical practice, myocardial dysfunction is often less obvious than neurological injury and may easily be overlooked during the initial stabilization period. Nevertheless, subtle reductions in cardiac output may have important consequences for cerebral oxygen delivery during the hours in which secondary brain injury evolves.
Myocardial injury following perinatal asphyxia is multifactorial and evolves over several phases.
Primary hypoxic injury
Reduced oxygen delivery results in:
Reperfusion injury
Following restoration of circulation:
Secondary inflammatory phase
Over subsequent hours:
These mechanisms resemble those described in adult post-cardiac arrest syndrome and contribute to transient or prolonged ventricular dysfunction.
Cardiovascular abnormalities occur frequently in infants with moderate and severe HIE.
Clinical manifestations include:
However, overt circulatory collapse represents only the most severe end of a broad haemodynamic spectrum.
Neonatologists are familiar with infants who maintain acceptable arterial pressures while simultaneously demonstrating persistent metabolic acidosis, prolonged capillary refill, and reduced urine output. Such observations illustrate the limitations of blood pressure as a surrogate for adequate systemic perfusion.
This phenomenon has important implications for neonatal neurocritical care because cerebral oxygen delivery depends primarily on cardiac output rather than arterial pressure alone
Table 2. Cardiovascular manifestations in neonatal HIE
Cardiovascular finding | Mechanism | Potential neurological consequence |
Left ventricular dysfunction | Myocardial ischemia | Reduced cerebral blood flow |
Right ventricular dysfunction | Increased pulmonary vascular resistance | Reduced systemic oxygen delivery |
Pulmonary hypertension | Pulmonary vasoconstriction | Hypoxaemia |
Tricuspid regurgitation | RV pressure overload | Reduced cardiac efficiency |
Bradycardia during cooling | Hypothermia-induced physiological response | Usually benign |
Low cardiac output syndrome | Myocardial stunning | Secondary brain injury |
Left ventricular dysfunction is among the most frequently reported cardiovascular abnormalities in HIE.
Functional echocardiographic studies have demonstrated:
The resulting reduction in systemic blood flow may compromise cerebral perfusion during the latent phase of injury, a period during which secondary neuronal injury remains potentially modifiable.
This observation raises an important clinical question:
Should haemodynamic support in HIE target blood pressure, cardiac output, or cerebral oxygen delivery?
Increasingly, evidence suggests that focusing exclusively on blood pressure may overlook clinically important reductions in systemic perfusion.
Pulmonary vascular dysfunction is common after severe perinatal asphyxia.
Contributing mechanisms include:
Persistent pulmonary hypertension of the newborn (PPHN) occurs in a significant proportion of infants undergoing therapeutic hypothermia.
Elevated pulmonary vascular resistance increases right ventricular afterload, resulting in:
The interaction between pulmonary and systemic circulations highlights the complexity of haemodynamic management in these infants.
Biochemical markers have increasingly been used to assess myocardial involvement in HIE.
Cardiac Troponin I and Troponin T
Elevated troponin concentrations correlate with:
B-type Natriuretic Peptide (BNP)
BNP and NT-proBNP reflect:
These biomarkers may provide valuable adjunctive information when interpreted alongside echocardiographic findings.
Despite its limitations, blood pressure continues to dominate haemodynamic decision-making in many neonatal units, largely because it is continuously available and easy to interpret.
However, blood pressure alone provides limited information regarding:
An infant may maintain normal arterial pressure through increased systemic vascular resistance while simultaneously experiencing severe reductions in cardiac output.
Consequently, reliance on blood pressure alone may result in under-recognition of haemodynamic compromise.
The growing use of targeted neonatal echocardiography (TnECHO) has transformed haemodynamic assessment in neonatal intensive care.
Functional echocardiography allows bedside evaluation of:
In infants with HIE, TnECHO facilitates individualized haemodynamic management and may identify circulatory abnormalities before the onset of overt clinical deterioration.
Therapeutic hypothermia significantly alters cardiovascular physiology.
Expected physiological effects include:
Distinguishing physiological adaptation from pathological circulatory compromise may be challenging.
For example, a heart rate of 80–90 beats per minute during cooling may represent normal physiological slowing rather than cardiovascular instability.
This distinction is critical to avoid unnecessary interventions that may themselves adversely affect cerebral haemodynamics.
The recognition of cardiovascular dysfunction as a major determinant of neurological recovery represents an important shift in neonatal neurocritical care.
The objective is no longer simply maintaining blood pressure within an acceptable range.
Instead, modern haemodynamic management increasingly seeks to optimize:
Such an approach forms the foundation of precision haemodynamic management in HIE.
Although neurological injury understandably dominates clinical attention in neonatal HIE, the kidneys are among the organs most vulnerable to hypoxic-ischaemic insult. Owing to their high metabolic demands and dependence on continuous perfusion, the neonatal kidneys are particularly susceptible to reductions in oxygen delivery and systemic blood flow.
Contemporary studies suggest that acute kidney injury (AKI) develops in approximately one-third to one-half of infants with moderate to severe HIE, with reported incidences varying according to diagnostic criteria and patient populations. Importantly, therapeutic hypothermia does not eliminate the risk of renal injury, and AKI remains common even among cooled infants receiving modern neurocritical care.
For many years renal dysfunction was considered largely a consequence of severe perinatal asphyxia rather than a contributor to ongoing injury. This perception is gradually changing.Increasing evidence, however, suggests that AKI itself contributes to ongoing systemic inflammation, metabolic instability, and secondary organ injury.
The kidney should therefore be regarded not merely as a victim of hypoxia but as an active participant in the pathophysiology of HIE.
Several characteristics of neonatal renal physiology increase susceptibility to hypoxic injury.
These include:
During fetal adaptation to hypoxia, renal blood flow decreases significantly as circulation is preferentially redistributed toward the brain, heart, and adrenal glands. While this compensatory mechanism may preserve cerebral oxygenation during transient stress, prolonged reductions in renal perfusion rapidly lead to ischemic tubular injury.
The resulting damage predominantly affects the renal tubules, although glomerular and vascular injury may also occur in severe cases.
Renal injury in HIE is multifactorial and rarely attributable to ischemia alone.
Major contributors include:
Ischaemic injury
Reperfusion injury
Inflammatory activation
Haemodynamic instability
The coexistence of cardiac dysfunction and renal injury reinforces the concept of a neonatal cardio-renal syndrome occurring within the broader framework of HIE.
Diagnosing acute kidney injury in newborn infants remains frustratingly difficult, particularly during the first days of life when physiological adaptation and maternal creatinine transfer complicate interpretation of laboratory findings.
Traditional markers such as serum creatinine have several limitations:
Urine output monitoring is also imperfect because some infants develop non-oliguric AKI.
Consequently, clinicians may underestimate the true burden of renal injury during the early phase of HIE.
Table 4. Limitations of conventional AKI markers in neonates
Marker | Limitation |
Serum creatinine | Influenced by maternal creatinine |
Urine output | Poor sensitivity for non-oliguric AKI |
Blood urea nitrogen | Influenced by hydration and nutrition |
Fractional sodium excretion | Variable in preterm and sick neonates |
The search for earlier and more sensitive biomarkers has generated considerable interest in neonatal nephrology.
Promising biomarkers include:
Neutrophil gelatinase-associated lipocalin (NGAL)
One of the earliest markers of tubular injury and often rises before serum creatinine changes become apparent.
Cystatin C
Reflects glomerular filtration more accurately than creatinine and is less influenced by maternal physiology.
Kidney injury molecule-1 (KIM-1)
Associated with proximal tubular damage.
Interleukin-18
May provide additional information regarding inflammatory renal injury.
These biomarkers may eventually facilitate earlier diagnosis and allow more individualized management strategies.
Table 5. Emerging renal biomarkers in neonatal HIE
Biomarker | Primary role | Potential clinical utility |
NGAL | Tubular injury | Early detection of AKI |
Cystatin C | Glomerular filtration | Assessment of renal function |
KIM-1 | Tubular damage | Severity stratification |
IL-18 | Inflammation | Prediction of progression |
Urinary albumin | Glomerular injury | Monitoring renal recovery |
One of the more fascinating developments in neonatal physiology has been the recognition that the injured kidney and injured brain communicate in ways that extend far beyond simple haemodynamics.
Experimental models suggest that renal injury may influence neurological outcomes through several mechanisms:
Similarly, severe cerebral injury may alter renal perfusion through autonomic dysregulation and neurohumoral activation.
This reciprocal interaction forms a central component of the emerging cardio-renal-brain axis.
Therapeutic hypothermia influences renal physiology in several important ways.
Potential effects include:
Although cooling may exert some protective effects on renal tissue, current evidence remains inconclusive regarding its ability to prevent AKI.
From a practical standpoint, clinicians must remain aware that therapeutic hypothermia may substantially alter the pharmacokinetics of commonly used medications including:
Renal dysfunction further amplifies this variability, creating significant challenges for individualized dosing.
The interaction between HIE, hypothermia, and renal dysfunction introduces considerable complexity into neonatal pharmacotherapy.
Standard dosing regimens may not adequately account for:
Future precision medicine approaches may integrate:
Such strategies align closely with the broader principles of precision neurocritical care.
Although neurological outcomes dominate follow-up programmes for survivors of HIE, increasing attention is being directed toward long-term renal health.
Potential consequences include:
Whether early renal injury contributes directly to adverse neurodevelopmental outcomes remains an active area of investigation.
Recognition of AKI as an active contributor rather than a passive marker of disease severity has important implications for neonatal practice.
Management should include:
Such an approach supports the transition from isolated organ management toward systems-based neurocritical care.
Although the concept of HIE has evolved beyond a purely neurological disorder, Although neonatal encephalopathy is increasingly recognized as a multisystem disorder, long-term outcome remains largely determined by the extent of cerebral recovery.
What has changed is our understanding of how cerebral injury develops and progresses.
The neonatal brain does not exist in physiological isolation. Cerebral oxygen delivery depends on an intricate balance between:
Disturbance of any component of this network may influence the trajectory of neurological recovery following hypoxic-ischaemic injury.
The challenge for modern neurocritical care is therefore not simply to protect neurons, but to preserve the physiological environment in which neuronal recovery can occur.
The pathophysiology of HIE is traditionally described as a biphasic process consisting of primary and secondary energy failure.
Primary Energy Failure
During the initial hypoxic-ischaemic insult:
Failure of ATP-dependent ion pumps results in:
If the insult is sufficiently severe, immediate cell death occurs.
Latent Phase
Following successful resuscitation, a transient period of partial metabolic recovery may occur.
This latent phase typically lasts approximately 6 hours and represents the therapeutic window during which interventions such as therapeutic hypothermia exert their greatest benefit.
Importantly, haemodynamic instability during this period may significantly influence subsequent injury progression.
Secondary Energy Failure
Secondary injury develops over the following 6 to 72 hours and is characterized by:
Unlike primary injury, many components of secondary energy failure remain potentially modifiable.
This principle forms the biological basis of contemporary neuroprotective strategies.
Figure 8. Temporal evolution of cerebral injury following perinatal asphyxia
Hypoxic-Ischaemic Event
↓
Primary Energy Failure
↓
Partial Recovery
(Latent Phase)
↓
Secondary Energy Failure
↓
Inflammation
Oxidative Stress
Mitochondrial Dysfunction
↓
Neuronal Death
↓
Neurodevelopmental Outcome
Under normal physiological conditions, cerebral autoregulation maintains relatively stable cerebral blood flow despite fluctuations in systemic blood pressure.
This mechanism depends upon:
In healthy neonates, autoregulation allows the brain to maintain adequate perfusion across a range of systemic pressures.
This protective mechanism minimizes both ischemic injury and hyperperfusion-related damage.
Hypoxic-ischaemic injury disrupts cerebral autoregulatory mechanisms through multiple pathways:
As autoregulation fails, cerebral blood flow becomes increasingly pressure-passive.
Under these conditions:
This loss of autoregulatory reserve may explain why infants with apparently stable systemic parameters occasionally experience unexpected neurological deterioration.
Figure 9. Cerebral autoregulation in health and HIE
Healthy Neonate
Blood Pressure Changes
↓
Autoregulation Maintained
↓
Stable Cerebral Blood Flow
HIE
Blood Pressure Changes
↓
Loss of Autoregulation
↓
Pressure-Passive Circulation
↓
Cerebral Hypoperfusion or Hyperperfusion
For decades, clinicians have relied heavily on arterial blood pressure as a marker of adequate cerebral perfusion. The relationship between the two, however, is considerably more complex.
However, cerebral oxygen delivery depends more fundamentally upon:
Cerebral Oxygen Delivery = Cardiac Output × Arterial Oxygen Content
Consequently:
These observations reinforce the importance of integrating cardiac assessment into neurocritical care.
Table 6. Determinants of cerebral oxygen delivery
Variable | Clinical relevance |
Cardiac output | Primary determinant of cerebral perfusion |
Hemoglobin concentration | Determines oxygen carrying capacity |
Arterial oxygen saturation | Influences oxygen content |
Cerebral autoregulation | Maintains stable blood flow |
Pulmonary vascular resistance | Affects systemic oxygen delivery |
Secondary brain injury involves complex interactions between the central nervous system and peripheral organs.
Inflammatory mediators released following myocardial injury and acute kidney injury may contribute to:
Similarly, severe cerebral injury may induce:
These interactions create a self-perpetuating cycle of systemic injury and neurological deterioration.
Figure 10. Inflammatory amplification within the cardio-renal-brain axis
Myocardial Injury
↓
Inflammatory Cytokines
↓
Blood-Brain Barrier Dysfunction
↓
Neuroinflammation
↓
Neuronal Injury
↓
Autonomic Dysregulation
↓
Further Cardiovascular Instability
Near infrared spectroscopy (NIRS) has emerged as an important tool for continuous assessment of cerebral oxygenation.
Potential advantages include:
When combined with:
NIRS may contribute to individualized haemodynamic management strategies.
Table 7. Monitoring modalities in neonatal neurocritical care
Modality | Primary information provided |
TnECHO | Cardiac function and output |
NIRS | Cerebral oxygenation |
aEEG | Electrical brain activity |
Continuous EEG | Seizure detection |
Lactate | Global perfusion |
Troponin | Myocardial injury |
NGAL | Renal injury |
Several biomarkers have been investigated as indicators of neurological injury severity.
Promising candidates include:
Although these biomarkers remain largely investigational, future integration with cardiac and renal biomarkers may improve risk stratification.
The concept of a universal blood pressure threshold for all infants with HIE is increasingly being questioned.
Future haemodynamic management may instead involve individualized targets based upon:
Such an approach represents a fundamental shift from protocol-driven care toward precision neurocritical medicine.
Preserving cerebral recovery requires more than preventing seizures and initiating therapeutic hypothermia.
Optimal neuroprotection may depend equally upon:
The injured brain ultimately reflects the health of the entire physiological network supporting it.
The introduction of therapeutic hypothermia (TH) fundamentally changed the landscape of neonatal neurocritical care. By reducing cerebral metabolism and interrupting pathways involved in secondary energy failure, TH remains the only intervention consistently shown to improve survival and neurodevelopmental outcomes in infants with moderate and severe HIE.
The standard protocol of cooling to 33–34°C for 72 hours followed by gradual rewarming has become routine practice across neonatal intensive care units worldwide.
However, therapeutic hypothermia was designed primarily as a neuroprotective intervention. Its physiological effects extend far beyond the brain, influencing virtually every organ system involved in the cardio-renal-brain axis.
Understanding these systemic effects is essential for individualized patient management.
Therapeutic hypothermia creates a physiological state that differs substantially from normal neonatal adaptation, and many of the resulting cardiovascular changes should be interpreted within this context rather than automatically regarded as evidence of disease
Expected findings include:
The challenge for clinicians lies in distinguishing normal adaptation from clinically significant circulatory compromise.
For example, a heart rate of 85 beats per minute during cooling may represent an expected physiological response, whereas the same heart rate in a normothermic infant could suggest significant illness.
Clinical context therefore becomes critically important.
Table 9. Expected cardiovascular effects of therapeutic hypothermia
Physiological parameter | Expected response during cooling |
Heart rate | Decreases |
Systemic vascular resistance | Increases |
Metabolic rate | Decreases |
Oxygen consumption | Decreases |
Cardiac output | Mild reduction |
Lactate production | Usually decreases over time |
The interaction between therapeutic hypothermia and myocardial function remains complex.
Potential beneficial effects include:
Conversely, cooling may also:
Infants with significant myocardial injury may therefore exhibit haemodynamic deterioration during cooling despite apparent neurological stability.
These observations further support the role of serial functional echocardiography during therapeutic hypothermia.
Figure 11. Cardiovascular effects of therapeutic hypothermia
Therapeutic Hypothermia
↓
Reduced Metabolic Demand
↓
Reduced Oxygen Consumption
↓
Lower Heart Rate
↓
Increased Systemic Vascular Resistance
↓
Potential Reduction in Cardiac Output
↓
Influence on Cerebral and Renal Perfusion
Therapeutic hypothermia also influences renal function through several mechanisms.
Observed effects include:
Although these changes may partially reflect physiological adaptation, they may also complicate the diagnosis of evolving acute kidney injury.
Interpretation of serum creatinine concentrations becomes particularly challenging during cooling because both hypothermia and renal injury influence creatinine kinetics.
Perhaps one of the most underappreciated consequences of therapeutic hypothermia is its effect on drug disposition.
Cooling alters:
Table 10. Medications affected by therapeutic hypothermia
Medication | Major pharmacokinetic effect |
Morphine | Reduced clearance |
Phenobarbital | Prolonged half-life |
Midazolam | Reduced metabolism |
Gentamicin | Reduced renal clearance |
Amikacin | Reduced renal clearance |
Vancomycin | Increased accumulation risk |
These changes become even more pronounced in the presence of acute kidney injury or hepatic dysfunction.
A precision pharmacology approach may therefore become increasingly important in future neurocritical care practice.
In many units, considerable attention is understandably devoted to the initiation of cooling therapy, yet experienced clinicians often regard the rewarming phase as equally deserving of vigilance.
Rewarming induces several physiological changes:
Rapid rewarming may theoretically contribute to:
For these reasons, gradual and carefully monitored rewarming remains standard practice.
Figure 12. Physiological changes during rewarming
Rewarming
↓
Increased Metabolic Demand
↓
Increased Oxygen Consumption
↓
Increased Cardiac Workload
↓
Potential Haemodynamic Instability
↓
Risk of Secondary Cerebral Injury
Therapeutic hypothermia modifies interactions between all components of the cardio-renal-brain axis.
Examples include:
Heart → Brain : Reduced cardiac output may influence cerebral oxygen delivery.
Kidney → Brain: Reduced renal clearance alters anticonvulsant pharmacokinetics and fluid balance.
Brain → Heart: Autonomic dysregulation may contribute to cardiovascular instability.
Heart → Kidney: Reduced systemic blood flow may worsen renal perfusion.
The physiological state of each organ therefore influences the others.
Figure 13. Organ interactions during therapeutic hypothermia
Brain
▲
│
│
Heart ◄─────┼─────► Kidney
│
│
▼
Therapeutic Hypothermia
The complexity of these interactions challenges traditional approaches based solely on blood pressure and routine laboratory testing.
Increasingly, experts advocate multimodal monitoring involving:
Such an approach provides a more comprehensive understanding of the physiological state of the infant.
Table 11. Multimodal monitoring during therapeutic hypothermia
Monitoring modality | Organ system assessed | Potential clinical value |
TnECHO | Heart | Cardiac output and ventricular function |
NIRS | Brain | Cerebral oxygenation |
EEG/aEEG | Brain | Seizures and cerebral function |
Lactate | Global | Tissue perfusion |
Troponin | Heart | Myocardial injury |
NGAL | Kidney | Early AKI detection |
Current cooling protocols largely apply identical management strategies to all infants meeting eligibility criteria.
Yet considerable heterogeneity exists in:
Future care may therefore shift toward individualized physiological targets rather than standardized treatment algorithms.
Potential components include:
Therapeutic hypothermia should no longer be viewed simply as a cooling intervention.
Rather, it represents a complex physiological state that modifies interactions among the cardiovascular, renal, and neurological systems.
Successful neuroprotection depends not only on reducing cerebral metabolism but also on maintaining systemic conditions that support recovery throughout the entire cardio-renal-brain axis.
One of the most striking observations in neonatal neurocritical care is the considerable variability in outcomes among infants with apparently similar degrees of encephalopathy.
Two infants may:
yet experience markedly different neurodevelopmental trajectories.
This variability reflects the biological heterogeneity of HIE itself.
Differences in:
may all influence recovery.
These observations have driven increasing interest in precision neurocritical care, an approach that seeks to tailor treatment according to the physiological characteristics of the individual infant rather than relying solely on standardized protocols.
Traditional haemodynamic management has often focused on maintaining arterial blood pressure above predefined thresholds.
However, blood pressure alone provides limited information regarding:
Future management strategies may instead aim to optimize:
The objective shifts from achieving normal numbers to maintaining optimal physiology.
Figure 14. Evolution of haemodynamic targets in neonatal HIE
Traditional Approach
--------------------
Blood Pressure
↓
Treatment Decisions
Precision Approach
------------------
Cardiac Output
+ Cerebral Oxygenation
+ Autoregulation
+ Renal Function
+ Biomarkers
↓
Individualized Therapy
Targeted neonatal echocardiography (TnECHO) has emerged as one of the most important advances in neonatal haemodynamic assessment.
Unlike conventional echocardiography, which primarily evaluates structural abnormalities, TnECHO focuses on functional cardiovascular physiology.
Parameters that may guide management include:
Repeated assessments allow clinicians to identify evolving physiological changes and adjust treatment accordingly.
Table 12. Potential applications of TnECHO in HIE
Clinical question | Echocardiographic assessment |
Is cardiac output adequate? | Ventricular output measurements |
Is hypotension due to myocardial dysfunction? | Ventricular performance assessment |
Is pulmonary hypertension present? | Pulmonary pressure estimation |
Does the ductus contribute to instability? | Ductal flow pattern |
Is fluid responsiveness likely? | Preload assessment |
Near-infrared spectroscopy offers continuous bedside monitoring of regional cerebral oxygen saturation.
Potential applications include:
The combination of NIRS and echocardiography may provide valuable insight into the relationship between systemic circulation and cerebral oxygen delivery.
Figure 15. Multimodal physiological monitoring in precision neurocritical care
Targeted Echocardiography
+
Cerebral NIRS
+
Continuous EEG
+
Biomarkers
+
Laboratory Trends
+
Clinical Examination
↓
Integrated Physiological Profile
↓
Individualized Treatment Strategy
Current practice often relies on isolated biomarkers.
Future strategies may involve integrated biomarker panels representing multiple organ systems.
Table 13. Proposed biomarker panel for the cardio-renal-brain axis
Organ system | Biomarker | Clinical purpose |
Brain | NSE | Neuronal injury |
Brain | GFAP | Astrocytic injury |
Heart | Troponin I | Myocardial injury |
Heart | NT-proBNP | Ventricular strain |
Kidney | NGAL | Early AKI detection |
Kidney | Cystatin C | Renal filtration |
Systemic | Lactate | Global perfusion |
Inflammatory | IL-6 | Systemic inflammation |
Drug disposition in infants with HIE is highly dynamic.
Factors influencing pharmacokinetics include:
As a result, standard dosing schedules may lead to either under-treatment or toxicity.
Future pharmacological strategies may incorporate:
Such approaches are particularly relevant for anticonvulsants, sedatives, and antimicrobials.
Artificial intelligence has generated considerable excitement within critical care medicine, although its eventual role within neonatal practice remains to be fully defined
Potential applications in HIE include:
One potential advantage of machine learning approaches lies in their ability to identify complex physiological patterns that are difficult for clinicians to recognize in real time.
Figure 16. Artificial intelligence within the cardio-renal-brain axis
Clinical Data
+
Laboratory Results
+
Physiological Monitoring
+
Imaging
+
Biomarkers
↓
Machine Learning Algorithms
↓
Risk Prediction
↓
Clinical Decision Support
↓
Precision Neurocritical Care
Although still largely confined to research environments, the concept of the digital twin offers an intriguing glimpse into the future of individualized intensive care.
A digital twin is a virtual physiological model of an individual patient that continuously updates using real-time clinical data.
In theory, such systems could simulate:
Clinicians could therefore test therapeutic strategies within a virtual environment before applying them to the patient.
Although currently experimental, this technology may eventually redefine individualized neonatal care.
Several barriers remain before precision neurocritical care becomes routine practice.
These include:
Multicentre collaborative research will be essential to address these limitations.
Table 14. Barriers to implementation of precision neurocritical care
Challenge | Potential solution |
Limited expertise | Training programmes |
Cost of monitoring | Technology development |
Data overload | AI-assisted interpretation |
Lack of evidence | Prospective trials |
Variable practice patterns | Consensus guidelines |
Perhaps the greatest contribution of precision neurocritical care lies not in technology itself but in the change in clinical philosophy that accompanies it.
The question is no longer:
"Is the blood pressure normal?"
but rather:
"Is this infant receiving the physiological support required for neurological recovery?"
This represents a subtle but profound shift in the way clinicians approach neonatal brain injury.
The success of therapeutic hypothermia has undoubtedly transformed neonatal care, yet it has also exposed the limitations of our current understanding of HIE. Despite standardized cooling protocols and improvements in neonatal intensive care, a substantial proportion of affected infants continue to experience death or significant neurodevelopmental impairment.
These observations suggest that neuroprotection alone may not be sufficient.
Future progress will likely depend upon a broader physiological approach that recognizes the interconnected nature of cerebral, cardiovascular, and renal function following perinatal hypoxia-ischaemia.
The emerging cardio-renal-brain axis provides a framework for this transition.
One of the most important unanswered questions in neonatal neurocritical care concerns haemodynamic goals.
Current practice often relies on arbitrary blood pressure thresholds derived from gestational age or birth weight.
However, these values may not accurately reflect:
Future studies should attempt to define:
Table 15. Key unanswered haemodynamic questions in HIE
Clinical Question | Current Status |
What is the optimal blood pressure target? | Unknown |
Should treatment target cardiac output rather than blood pressure? | Under investigation |
Can cerebral oxygenation guide vasoactive therapy? | Promising but unproven |
How should pulmonary hypertension influence haemodynamic targets? | Limited evidence |
Can multimodal monitoring improve outcomes? | Requires prospective trials |
Although numerous biomarkers have shown promise individually, few have been validated as components of an integrated physiological model.
Future research priorities include:
The ideal biomarker panel would provide real-time information regarding:
Figure 17. Proposed integrated biomarker model
Brain Biomarkers
(NSE, GFAP, S100B)
+
Cardiac Biomarkers
(Troponin, BNP)
+
Renal Biomarkers
(NGAL, Cystatin C)
+
Inflammatory Biomarkers
(IL-6, TNF-α)
↓
Integrated Risk Stratification
↓
Personalized Therapy
Therapeutic hypothermia represents a uniform intervention applied to a biologically heterogeneous population.
Future approaches may involve tailoring therapy according to:
Potential individualized interventions may include:
Such strategies move beyond protocol-based treatment toward true precision medicine.
Modern neonatal intensive care units generate enormous quantities of physiological data.
These include:
Human clinicians may struggle to integrate these data streams in real time.
Artificial intelligence offers the possibility of:
Importantly, AI should be viewed as a clinical support tool rather than a replacement for clinical judgment.
One potential future direction involves creation of a composite physiological score incorporating:
Cardiovascular variables
Renal variables
Neurological variables
Such a score may provide a more comprehensive assessment of disease severity than existing neurological staging systems alone.
Table 16. Proposed components of a neonatal cardio-renal-brain score
Domain | Example Variables |
Cardiac | Cardiac output, troponin, ventricular function |
Renal | Creatinine, NGAL, urine output |
Cerebral | aEEG, NIRS, MRI findings |
Systemic | Lactate, inflammatory markers |
The rarity of severe HIE within individual centres presents important research challenges.
Progress will require:
Large multicentre studies will be essential for validating emerging technologies and determining their impact on long-term outcomes.
Historically, studies in HIE have focused primarily on mortality and severe disability.
Future research should also consider:
The concept of survivorship in neonatology continues to evolve.
Protecting the brain remains essential, but preserving lifelong health across multiple organ systems may become equally important.
Figure 18. The future vision of neonatal precision neurocritical care
Multimodal Monitoring
+
Biomarkers
+
Targeted Echocardiography
+
Artificial Intelligence
+
Precision Pharmacology
↓
Individualized Physiological Support
↓
Improved Long-Term Outcomes
Hypoxic-ischaemic encephalopathy has traditionally been regarded as a disease of the brain. Increasing evidence, however, suggests that this perspective is incomplete.
Perinatal hypoxia-ischaemia initiates a complex multisystem response involving the heart, kidneys, and brain, with each organ influencing the function and recovery of the others through haemodynamic, metabolic, inflammatory, and neurohumoral pathways.
Myocardial dysfunction may compromise cerebral perfusion during the vulnerable period of secondary energy failure, while acute kidney injury contributes to metabolic instability, altered pharmacokinetics, and systemic inflammation. Therapeutic hypothermia, although neuroprotective, further modifies these interactions by altering cardiovascular physiology and renal function.
Recognition of this interconnected physiology supports the emergence of the neonatal cardio-renal-brain axis as a new conceptual framework for understanding HIE.
The implications are profound. Management strategies based solely on blood pressure targets or neurological examination may fail to capture the complexity of the critically ill infant undergoing neuroprotective care. Future progress is likely to depend upon integrated physiological monitoring, multimodal biomarkers, precision pharmacology, and individualized haemodynamic support.
The future of neonatal neurocritical care may therefore lie not in treating the injured brain in isolation, but in preserving the integrity of the physiological network that sustains cerebral recovery.
The recognition of a neonatal cardio-renal-brain axis carries implications that extend beyond physiology and into everyday clinical practice. Although many of the concepts discussed in this review remain under active investigation, several practical principles can already be incorporated into contemporary neonatal neurocritical care.
For decades, blood pressure has served as the principal haemodynamic target in infants with HIE. However, arterial pressure alone provides limited insight into systemic blood flow or cerebral oxygen delivery.
Particular caution should be exercised in infants who demonstrate:
despite apparently acceptable blood pressure values.
In such situations, occult low cardiac output should be considered.
Targeted neonatal echocardiography may identify important haemodynamic abnormalities that are not evident on routine clinical assessment.
Potential indications include:
Serial assessments may provide greater clinical value than isolated examinations because cardiovascular physiology evolves rapidly during the first 72 hours following injury.
Renal dysfunction frequently develops early in the course of neonatal encephalopathy and may remain clinically silent during the initial phase of illness.
Routine assessment should include:
Particular attention should be paid during therapeutic hypothermia, when changes in renal clearance may significantly alter drug exposure.
Therapeutic hypothermia alters cardiovascular, renal, metabolic, and pharmacological physiology.
Bradycardia during cooling should be interpreted within the clinical context and should not automatically trigger intervention in otherwise stable infants.
Similarly, reductions in urine output or changes in serum creatinine should be interpreted cautiously during cooling and rewarming.
Clinical trends often provide more useful information than isolated measurements.
The period of rewarming is sometimes viewed as the conclusion of active neurocritical care.
In reality, important physiological changes continue to occur during this stage.
Clinicians should remain alert for:
Careful observation during rewarming may be as important as monitoring during the cooling phase itself.
No single physiological parameter adequately reflects the complexity of HIE.
Increasingly, management decisions may rely upon integration of multiple sources of information including:
The future of neonatal neurocritical care is likely to depend upon the interpretation of these physiological signals as an integrated system rather than as isolated variables.
Table 17. Suggested bedside assessment of the cardio-renal-brain axis in neonatal HIE
Domain | Assessment Tool | Suggested Frequency |
Cardiovascular | Clinical perfusion assessment | Continuous |
Cardiovascular | TnECHO | At admission and as clinically indicated |
Cardiovascular | Lactate | Every 6–12 hours |
Neurological | Neurological examination | Every 4–6 hours |
Neurological | aEEG/EEG | Continuous during cooling |
Neurological | Cerebral NIRS | Continuous if available |
Renal | Urine output | Hourly |
Renal | Serum creatinine and electrolytes | Daily |
Renal | Renal biomarkers (where available) | According to local practice |
Perhaps the most important implication of the cardio-renal-brain axis is conceptual rather than technological.
The question facing the clinician is no longer simply:
"Has the infant met criteria for therapeutic hypothermia?"
but increasingly:
"Are we providing the physiological conditions required for cerebral recovery?"
This subtle shift in perspective may ultimately prove to be one of the most important developments in neonatal neurocritical care over the coming decade.
This research received no external funding.
The author declares no conflict of interest.
No new datasets were generated or analysed during the preparation of this narrative review.
The author used artificial intelligence-assisted language support tools during manuscript preparation for drafting assistance and language refinement. All scientific content, interpretation, critical appraisal, and final manuscript approval were performed solely by the author, who accepts full responsibility for the accuracy and integrity of the work.
Conceptualization: A.R.K.;
Literature review and synthesis: A.R.K.;
Writing—original draft preparation: A.R.K.;
Writing—review and editing: A.R.K.;
Visualization: A.R.K.;
Supervision: A.R.K.
The author has read and approved the final version of the manuscript.
Foundational HIE and Therapeutic Hypothermia Studies
[1] S. Shankaran et al., "Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy," New England Journal of Medicine, vol. 353, no. 15, pp. 1574–1584, 2005, doi: 10.1056/NEJMcps050929.
[2] D. Azzopardi et al., "Moderate hypothermia to treat perinatal asphyxial encephalopathy," New England Journal of Medicine, vol. 361, no. 14, pp. 1349–1358, 2009, doi: 10.1056/NEJMoa0900854.
[3] D. Azzopardi et al., "Effects of hypothermia for perinatal asphyxia on childhood outcomes," New England Journal of Medicine, vol. 371, no. 2, pp. 140–149, 2014, doi: 10.1056/NEJMoa1315788.
[4] A. J. Gunn and T. R. Gunn, "The pharmacology of neuronal rescue with cerebral hypothermia," Early Human Development, vol. 81, no. 5, pp. 413–418, 2005.
[5] S. L. Bonifacio and A. R. Laptook, "Neuroprotection for hypoxic-ischaemic encephalopathy," Seminars in Fetal and Neonatal Medicine, vol. 27, no. 5, 2022.
[6] J. L. Mathew et al., "Therapeutic hypothermia in neonatal hypoxic encephalopathy," Archives of Disease in Childhood Fetal and Neonatal Edition, 2022.
[7] J. M. Korf et al., "A narrative review on treatment strategies for neonatal hypoxic-ischaemic encephalopathy," Translational Pediatrics, vol. 12, 2023.
Pathophysiology of HIE
[8] H. Hagberg, C. Mallard, D. M. Ferriero, S. J. Vannucci, and M. Levison, "The role of inflammation in perinatal brain injury," Nature Reviews Neurology, vol. 11, pp. 192–208, 2015.
[9] D. M. Ferriero, "Neonatal brain injury," New England Journal of Medicine, vol. 351, pp. 1985–1995, 2004.
[10] H. Hagberg, E. Bona, C. Mallard, and M. Thoresen, "Hypoxia-ischaemia model in the immature brain," Acta Paediatrica, vol. 96, pp. 154–157, 2007.
[11] A. R. Laptook, "The resuscitation and post-resuscitation management of neonatal hypoxic-ischaemic encephalopathy," Clinics in Perinatology, vol. 43, pp. 529–545, 2016.
Cardiovascular Dysfunction and Hemodynamics
[12] L. Mertens et al., "Targeted neonatal echocardiography in the neonatal intensive care unit: practice guidelines and recommendations for training," European Heart Journal Cardiovascular Imaging, vol. 12, no. 10, pp. 715–736, 2011.
[13] P. J. McNamara et al., "Guidelines and recommendations for targeted neonatal echocardiography," Journal of the American Society of Echocardiography, 2024.
[14] P. T. Levy et al., "Application of neonatologist performed echocardiography in the assessment and management of neonatal hemodynamics," Journal of Perinatology, vol. 38, pp. 85–96, 2018.
[15] P. J. McNamara and A. Sehgal, "Towards rational management of the patent ductus arteriosus: the need for disease staging," Archives of Disease in Childhood Fetal and Neonatal Edition, vol. 92, pp. F424–F427, 2007.
[16] P. J. McNamara, "Hemodynamic instability in the critically ill neonate," Seminars in Fetal and Neonatal Medicine, vol. 19, pp. 154–159, 2014.
[17] A. Sehgal and P. J. McNamara, "The use of targeted neonatal echocardiography in neonatal intensive care units," Current Pediatric Reviews, vol. 14, pp. 88–95, 2018.
[18] "Targeted Neonatal Echocardiography in Patients With Neonatal Encephalopathy," Pediatrics, vol. 150, Supplement 2, 2022.
Pulmonary Hypertension in HIE
[19] N. Lakshminrusimha and S. Keszler, "Persistent pulmonary hypertension of the newborn," NeoReviews, vol. 16, pp. e680–e692, 2015.
[20] N. Lakshminrusimha et al., "Pulmonary hypertension in neonatal hypoxic-ischaemic encephalopathy," Seminars in Fetal and Neonatal Medicine, vol. 21, pp. 182–189, 2016.
Acute Kidney Injury and Kidney-Brain Crosstalk
[21] D. J. Askenazi et al., "Acute kidney injury in critically ill newborns: what do we know? What do we need to learn?" Pediatric Nephrology, vol. 24, pp. 265–274, 2009.
[22] C. Coleman et al., "Neonatal acute kidney injury," Frontiers in Pediatrics, vol. 10, 2022.
[23] T. A. Forbes et al., "Neonatal acute kidney injury: diagnosis, recognition and future directions," Seminars in Nephrology, 2026.
[24] "Neonatal AKI: An update," Journal of Neonatal-Perinatal Medicine, 2024.
[25] C. Gupta et al., "A new approach to define acute kidney injury in term newborns with hypoxic-ischaemic encephalopathy," Pediatric Nephrology, vol. 31, pp. 1167–1178, 2016.
Biomarkers
[26] N. M. El Raggal et al., "Serum neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury in asphyxiated neonates," Indian Pediatrics, vol. 50, pp. 459–462, 2013.
[27] T. Yuniati et al., "Neutrophil gelatinase-associated lipocalin as a useful early biomarker for neonatal acute kidney injury," Neonatology and Perinatal Medicine, 2026.
[28] A. Chalak et al., "Biomarkers for neonatal hypoxic-ischaemic encephalopathy," Pediatric Neurology, vol. 61, pp. 1–9, 2016.
[29] S. Massaro et al., "Biomarkers of brain injury in neonatal encephalopathy," Clinics in Perinatology, vol. 41, pp. 123–140, 2014.
Cerebral Monitoring and Neurocritical Care
[30] J. Greisen, "Cerebral blood flow and oxygenation in infants after birth asphyxia," Acta Paediatrica, vol. 98, pp. 174–178, 2009.
[31] J. M. Perlman and S. Shah, "Hypoxic-ischaemic encephalopathy: challenges in neurocritical care," Journal of Pediatrics, vol. 174, pp. 12–17, 2016.
[32] M. Thoresen et al., "Cerebral oxygenation and autoregulation during therapeutic hypothermia," Pediatric Research, vol. 76, pp. 205–212, 2014.
[33] A. Chalak et al., "Cerebral autoregulation in neonatal encephalopathy," Pediatrics, vol. 142, no. 5, 2018.
Precision Medicine and Artificial Intelligence
[34] H. Al-Shehri et al., "Targeted neonatal echocardiography: a systematic review of clinical utility and outcomes," 2025.
[35] M. Sakr et al., "Neonatal therapeutic hypothermia," StatPearls Publishing, 2024.
[36] M. Fiammante et al., "A simple EEG-based decision tool for neonatal therapeutic hypothermia in hypoxic-ischaemic encephalopathy," 2024.
[37] R. Bao and Y. Ou, "Boston Neonatal Brain Injury Dataset for Hypoxic-Ischaemic Encephalopathy (BONBID-HIE): neurocognitive outcomes and NICU outcomes," 2024.